Medivir appoints new CEO

26 May 2020

Less than two year after engaging a new head of the company, Stockholm, Sweden-based biotech Medivir (Nasdaq: MVIR) has appointed a new chief executive, namely Yilmaz Mahshid.

Mr Mahshid has long and broad experience from qualified roles in the life science sector. He succeeds Uli Hacksell, who has been CEO since October 2018, and will assume his position in the fall. Dr Hacksell remains as a board member of Medivir.

Mr Mahshid joins Medivir from his recent position as chief financial at PledPharma. He was prior to that investment manager at Industrifonden. He has also worked as a health care analyst at Pareto Securities and at Öhman Fondkommission.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK